Back

Targeting IL-6 signalling from biological rationale to cardiovascular outcome trials

29 August 2026 (17:42 - 17:54)
Organised by: Logo
Congress Presentation Part of: Frontiers in anti-inflammatory therapies Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Paul M Ridker

Brigham and Women's Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Targeting inflammasome axis and NLRP3 inhibitors and IL-1 blockade in cardiovascular disease
Professor P. Libby (Boston, US)
Slides Video
Presentation thumbnail
Heart failure and immune-mediated syndrome: new insights and emerging targets
Professor J. Hill (Dallas, US)
Slides Video
Presentation thumbnail
Expanding frontiers in cardiometabolic therapy: SGLT2 inhibitors and GLP-1 receptor agonists
Professor V. Schini-Kerth (Strasbourg, FR)
Slides Video
Presentation thumbnail
Frontiers in anti-inflammatory therapies - discussion
Video

Access the full session

Session thumbnail
Frontiers in anti-inflammatory therapies
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 17:42 CET
You may be interested in
thumbnail
Congress Presentation
Novel pharmacological anti-inflammatory approaches: beyond IL-1 inhibition
31 August 2024
thumbnail
Congress Presentation
Interleukin-6 inclusion adds value to the SMART risk score for prediction of cardiovascular death in patients with established ASCVD
31 August 2025
thumbnail
Congress Presentation
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
10 May 2026
thumbnail
Congress Presentation
Targeting Interleukin-6 signalling in cardiovascular disease prevention.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources